ASCO's Government Relations Committee establishes policy priorities on an annual basis. These priorities are updated as needed to reflect emerging issues.

GOAL 1: Achieve a fair, adequate, and stable payment environment for oncology practice

  • Repeal the Sustainable Growth Rate (SGR)
  • Preserve the Average Sales Price formula for Part B drugs until appropriate payment reform alternatives are established that can keep oncology practices healthy
  • Advocate for the testing of a variety of Oncology Specific Alternative Payment Models (APMs)
  • Ensure any transition to a new payment model is phased in in a way that allows time to understand the new system’s impact before it is fully implemented
  • Pursue incentives that support optimum patient care including treatment summaries, care plans, preventative care, palliative care, survivorship care, and end of life planning
  • Monitor and pursue policies that ensure that treatments for cancer are available to all patients and that address drug shortages

GOAL 2: Ensure all cancer patients have access to high quality cancer care

  • Advocate for policies that protect patients with cancer from high cost-sharing requirements, especially as they relate to oral chemotherapy and supportive care medications.
  • Pursue policies that ensure that all patients with cancer, regardless of their health insurance coverage or ability to pay, have access to high quality services necessary to diagnose and treat their disease. These services include screening, vaccinations, tobacco cessation, appropriate genetic testing, and all phases of clinical trials
  • Prevent Health Insurance Exchanges and other state policies from creating barriers that prevent patients with cancer from accessing high quality health care
  • Ensure proper implementation of clinical trials coverage provisions in the Affordable Care Act and coverage of all phases of clinical trials
  • Work to develop incentives for physicians to offer and manage clinical trials, and advance initiatives to transform the clinical trials process

GOAL 3: Enhance and streamline meaningful quality reporting and practice improvement

  • Advocate for policies that will ensure that QOPI will continue to be a QCDR that fulfills the requirements of PQRS
  • Build awareness of and support for ASCO’s CancerLinQ by educating policymakers about its potential and progress
  • Work toward policies that provide incentives for participation in quality improvement activities, including QOPI and CancerLinQ. Advocate for policies that eliminate the requirement for practices to operate under multiple pathway and reporting systems
  • Ensure that ASCO is involved in developing nationally recognized quality measures
  • Address barriers to patient centered medical care, such as lack of interoperability of electronic medical records and HIPAA

GOAL 4: Advocate for stable and predictable funding for the federal agencies that support cancer research and drug development

  • Advocate for robust and sustainable increases in federal budgets for the NIH and FDA
  • Maintain Congressional support for federally funded cancer research as a top priority and a sustainable clinical trials system
  • Educate Congress about the value of Biomedical Research both for our national health, as well as the health of our economy
  • Educate Congress about the value of the Food and Drug Administration’s drug development, drug safety, and drug shortage prevention programs